Furthermore, bryostatin-1 enhances anti-tumor immunity by stimulating cytotoxic CD8+ T cells by inducing T cell proliferation and IL-2 receptor upregulation, which is dependent on PKC activation (14, 19–21). This evidence concerns the gene CD8A and neoplasm.